EP1532131B1 - Composes du type motilide - Google Patents

Composes du type motilide Download PDF

Info

Publication number
EP1532131B1
EP1532131B1 EP03755757A EP03755757A EP1532131B1 EP 1532131 B1 EP1532131 B1 EP 1532131B1 EP 03755757 A EP03755757 A EP 03755757A EP 03755757 A EP03755757 A EP 03755757A EP 1532131 B1 EP1532131 B1 EP 1532131B1
Authority
EP
European Patent Office
Prior art keywords
substituted
unsubstituted
ethyl
compound according
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03755757A
Other languages
German (de)
English (en)
Other versions
EP1532131A2 (fr
EP1532131A4 (fr
Inventor
Daniel Santi
Brian Metcalf
Christopher Carreras
Yaoquan Liu
Robert Mcdaniel
Eduardo J. Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to SI200331492T priority Critical patent/SI1532131T1/sl
Publication of EP1532131A2 publication Critical patent/EP1532131A2/fr
Publication of EP1532131A4 publication Critical patent/EP1532131A4/fr
Application granted granted Critical
Publication of EP1532131B1 publication Critical patent/EP1532131B1/fr
Priority to CY20091100165T priority patent/CY1108808T1/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin

Definitions

  • the present invention provides prokinetic agents with superior pharmacological and pharmacokinetic properties for the treatment of gastrointestinal motility disorders.
  • the invention relates to the fields of chemistry, medicinal chemistry, medicine, molecular biology, and pharmacology
  • Gastrointestinal motility regulates the orderly movement of ingested material through the gut to insure adequate absorption of nutrients, electrolytes and fluids. Appropriate transit through the esophagus, stomach, small intestine and colon depends on regional control of intraluminal pressure and several sphincters that regulate forward movement and prevent back-flow of GI contents. The normal GI motility pattern may be impaired by a variety of circumstances including disease and surgery.
  • Gastroparesis is the delayed emptying of stomach contents. Symptoms of gastroparesis include stomach upset, heartburn, nausea, and vomiting. Acute gastroparesis may be caused by, for example, drugs (e.g., opiates), viral enteritis, and hyperglycemia, and is usually managed by treating the underlying disease rather than the motility disorder. The most common causes of chronic gastroparesis are associated with long standing diabetes or idiopathic pseudo-obstruction, often with so-called "non-ulcer” or "functional" dyspepsia.
  • GERD refers to the varied clinical manifestations of reflux of stomach and duodenal contents into the esophagus. The most common symptoms are heartburn and dysphasia; blood loss may also occur from esophageal erosion. GERD may be associated with low tone and inappropriate relaxation of the lower esophageal sphincter and occurs with gastroparesis in about 40% of cases. In most cases, GERD appears to be treatable with agents that reduce the release of acidic irritant by the stomach (e.g., Prilosec) or agents that increase the tone of the lower esophageal sphincter (e.g., cisapride).
  • agents that reduce the release of acidic irritant by the stomach e.g., Prilosec
  • agents that increase the tone of the lower esophageal sphincter e.g., cisapride.
  • disorders whose symptoms include impaired gastrointestinal motility are anorexia, gall bladder stasis, postoperative paralytic ileus, scleroderma, intestinal pseudoobstruction, gastritis, emesis, and chronic constipation (colonic inertia).
  • MMC Migrating Motor Complexes
  • erythromycin A ( 1 ) has been known to cause GI side effects such as nausea, vomiting, and abdominal discomfort. Erythromycin A undergoes acid catalyzed degradation in the stomach, forming initially 8,9-anhydro-6,9-hemiacetal 2 (also known as erythromycin A enol ether) and then spiroketal 3, as shown in Scheme A.
  • the GI side effects are largely explained by motilin agonist activity in erythromycin A itself and hemiacetal 2. (Spiroketal 3 is inactive.)
  • Omura et al. "Gastrointestinal motor-stimulating activity of macrolide antibiotics and the structure-activity relationship," J. Antibiotics (1985) 38: 1631-2 , discloses the relative ability of erythromycin A, 9-dihydroerythromycin A, and other macrolides to stimulate gut contraction in conscious dogs.
  • 9-dihydroerythromycin A was reported to be 65% as active as erythromycin at a dose of 1 mg/kg.
  • 9-dihydroerythromycin cannot form an enol ether, it is clear that enol ether formation is not essential for motilide activity.
  • Erythromycin A is currently used to treat motility disorders, even though its antibacterial activity raises concerns over generation of resistant microorganisms.
  • 9-dihydroerythromycin also shows antibacterial activity, there are similar concerns with its use as a motilide.
  • erythromycin enol ether analogs have been prepared as motilides, including EM-523 ( 4 ); EM-574 ( 5 ); LY267,108 ( 6 ); GM-611 ( 7 ); and ABT-229 ( 8 ) whose structures are shown below. See U.S. Patent Nos. 5,578,579 ; 5,658,888 ; 5,922,849 ; 6,077,943 ; and 6,084,079 .
  • motilides of interest include lactam enol ethers and lactam epoxide derivatives. See U.S. Patent Nos. 5,712,253 ; 5,523,401 ; 5,523,418 ; 5,538,961 ; and 5,554,605 .
  • WO-A-00/63225 discloses macrolides represented by a Markush formula which partially overlaps with present formula (I), and their use as antimicrobial agents.
  • US-B2-6 437 151 discloses erythromycins with particular substituents in C-13 and their use for inter alia the reduction of gastric motility.
  • the present invention provides analogs of 9-dihydroerythromycin that meet this need.
  • R 1 is substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 2 -C 10 alkenyl, substituted or unsubstituted C 2 -C 10 alkynyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclo
  • R 2 is H, substituted or unsubstituted C 1 -C 5 alkyl, substituted or unsubstituted C 2 -C 5 alkenyl, substituted or unsubstituted C 2 -C 5 alkynyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclo
  • R 3 is H or OH
  • a compound of this invention for treating a disorder of gastric motility in a patient suffering therefrom.
  • a pharmaceutical composition comprising a compound of this invention and a pharmaceutically acceptable carrier.
  • compounds (I) of this invention are used for the preparation of a medicament for treating a gastric motility disorder in a subject.
  • a recombinant host cell that produces 11-deoxyerythromycins (particularly 11-deoxyerythromycin B), along with the modified polyketide synthase genes they express and the vectors that are used to engineer them.
  • the 11-deoxyerythromycins are useful as intermediates for the synthesis of compounds of this invention.
  • the recombinant host cell has an eryAI gene engineered by replacement of the ketoreductase domain in module 2 thereof with a cassette containing a dehydratase domain, an enoylreductase domain, and a ketoreductase domain.
  • a method of making 11-deoxyerythromycins comprising culturing such a recombinant host cell.
  • Alkyl means a straight or branched chain hydrocarbon moiety having the specified number of carbon atoms in the chain or, where the number of carbon atoms is not specified, up to 5 carbon atoms in the chain.
  • Alkenyl means a straight or branched chain hydrocarbon moiety having at least one carbon-carbon double bond and the specified number of carbon atoms in the chain or, where the number of carbon atoms is not specified, up to 5 carbon atoms in the chain.
  • Alkynyl means a straight or branched chain hydrocarbon moiety having at least one carbon-carbon triple bond and the specified number of carbon atoms in the chain or, where the number of carbon atoms is not specified, up to 5 carbon atoms in the chain.
  • Alkylaryl mean an aryl, heterocyclic, or heteroaryl group, as the case may be, bonded directly to an alkyl moiety, as in benzyl, phenethyl.
  • Aryl means a monocyclic or bicyclic aromatic hydrocarbon ring system having 6 to 12 carbon atoms in the ring portion, such as phenyl, napthyl, and biphenyl moieties, each of which is optionally substituted at one or more positions.
  • Cycloalkyl means an optionally substituted, saturated cyclic hydrocarbon ring system, preferably containing 1 to 3 rings and 3 to 7 carbons per ring which may be further fused with an unsaturated C 3 -C 7 carbocyclic ring.
  • exemplary cycloalkyl ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, and adamantyl.
  • Halogen or "halo" means fluorine, chlorine, bromine and iodine.
  • Heterocycle means an optionally substituted, fully saturated or unsaturated, aromatic or nonaromatic ring system, for example, which is a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring system, which has at least one heteroatom in at least one carbon atom-containing ring.
  • Heteroaryl means a heterocycle in which the ring system is aryl. Each ring of the heterocyclic group containing a heteroatom may have 1, 2 or 3 heteroatoms selected from N, O and S, where the N and S optionally may be oxidized and the N optionally may be quaternized.
  • Exemplary monocyclic heterocyclic ring systems include pyrrolidinyl, pyrrolyl, indolyl, pyrazolyl, oxetanyl, pyrazolinyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, oxazolidinyl, isoxazolinyl, isoxazolyl, thizaolyl, thiadiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, furyl, tetrahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxazepinyl, azepinyl, 4-piperidonyl, pyridinyl, N-oxo-pyridy
  • Preferred heterocyclo groups include pyridinyl, pyrazinyl, pyrimidinyl, pyrroyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, thiadiazolyl, oxadiazolyl, thienyl, furanyl, quinolinyl, isoquinolinyl.
  • “Pharmaceutically acceptable salt” means a salt of a compound suitable for pharmaceutical formulation. Suitable pharmaceutically acceptable salts include acid addition salts which may, for example, be formed by mixing a solution of a compound with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, benzoic acid, acetic acid, citric acid, tartaric acid, phosphoric acid, carbonic acid .
  • a pharmaceutically acceptable acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, benzoic acid, acetic acid, citric acid, tartaric acid, phosphoric acid, carbonic acid .
  • pharmaceutically acceptable salts may be formed by treatment of a solution of the compound with a solution of a pharmaceutically acceptable base, such as lithium hydroxide, sodium hydroxide, potassium hydroxide, tetraalkylammonium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, ammonia, alkylamines.
  • a pharmaceutically acceptable base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, tetraalkylammonium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, ammonia, alkylamines.
  • substituents and substitution patterns can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be synthesized by techniques known in the art as well as the methods set forth herein.
  • substituents include alkyl, alkenyl, alkynyl, aryl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, cycloalkyl-oxy, heterocyclooxy, alkanoyl, alkanoyloxy, amino, alkylamino quarternary ammonium, aralkylamino, cycloalkylamino, heterocycloamino, dialkylamino, alkanoylamino, thio, alkylthio, cycloalkylthio, heterocyclothio, ureido, nitro, cyano, carboxy, caroboxylalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, alkylsulfonyl, sulfonamindo, aryloxy, in addition to those specified herein.
  • the substituent may be further substituted, for example, by halo, hydroxy
  • prodrugs of the compounds of this invention are in general functional derivatives of the compounds that are readily convertible in vivo into the required compound. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, Bundgaard, ed., Elsevier, 1985 .
  • R 1 is substituted or unsubstituted C 1 -C 10 alkyl, substituted or unsubstituted C 2 -C 10 alkenyl, substituted or unsubstituted C 2 -C 10 alkynyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclo;
  • R 2 is H, ethyl, propyl, isopropyl, or 2-butyl;
  • R 3 is H or OH;
  • R 1 is substituted or unsubstituted C 1 -C 5 alkyl
  • R 2 is H, substituted or unsubstituted C 1 -C 5 alkyl, substituted or unsubstituted C 2 -C 5 alkenyl, or substituted or unsubstituted C 2 -C 5 alkynyl
  • R 3 is H or OH
  • R 1 is ethyl
  • R 2 is substituted or unsubstituted C 2 -C 5 alkyl, substituted or unsubstituted C 2 -C 5 alkenyl, or substituted or unsubstituted C 2 -C 5 alkynyl
  • R 3 is H or OH
  • R 1 is ethyl
  • R 2 is ethyl, propyl, isopropyl, or 2-butyl
  • R 3 is H or OH
  • R 1 is substituted ethyl
  • R 2 is H, substituted or unsubstituted C 1 -C 5 alkyl, substituted or unsubstituted C 2 -C 5 alkenyl, or substituted or unsubstituted C 2 -C 5 alkynyl
  • R 3 is H or OH
  • R 1 is fluoroethyl or azidoethyl
  • R 2 is H, substituted or unsubstituted C 1 -C 5 alkyl, substituted or unsubstituted C 2 -C 5 alkenyl, or substituted or unsubstituted C 2 -C 5 akynyl
  • R 3 is H or OH
  • R 1 is substituted ethyl
  • R 2 is H, ethyl, propyl, isopropyl, or 2-butyl
  • R 3 is H or OH
  • R 1 is fluoroethyl or azidoethyl
  • R 2 is H, ethyl, propyl, isopropyl, or 2-butyl
  • R 3 is H or OH
  • R 1 is propyl
  • R 2 is H, substituted or unsubstituted C 1 -C 5 alkyl, substituted or unsubstituted C 2 -C 5 alkenyl, or substituted or unsubstituted C 2 -C 5 alkynyl
  • R 3 is H or OH
  • R 1 is propyl
  • R 2 is H, ethyl, propyl, isopropyl, or 2-butyl
  • R 3 is H or OH
  • R 1 is vinyl, butyl, benzyl, but-3-en-1-yl, phenyl, or 4-hydroxyphenyl
  • R 2 is H, substituted or unsubstituted C 1 -C 5 alkyl, substituted or unsubstituted C 2 -C 5 alkenyl, or substituted or unsubstituted C 2 -C 5 alkynyl
  • R 3 is H or OH
  • R 1 is vinyl, butyl, benzyl, but-3-en-1-yl, phenyl, or 4-hydroxyphenyl
  • R 2 is H, ethyl, propyl, isopropyl, or 2-butyl
  • R 3 is H or OH
  • R 3 and R 4 are independently H or OH;
  • R 1 is selected from the group consisting of ethyl, 2-fluoroethyl, and 1-propyl; and
  • R 2 is selected from the group consisting of methyl, ethyl, isopropyl, and 2-butyl; with the proviso that when R 1 is ethyl and R 3 is OH, then R 2 is not methyl.
  • R 1 is substituted or unsubstituted C 1 -C 5 alkyl (preferably ethyl);
  • R 2 is H, methyl, ethyl, propyl, isopropyl, or 2-butyl;
  • R 3 is H; and
  • R 4 is H or OH.
  • the compounds of formula (I) are prepared from the corresponding erythromycins (II) as illustrated in Scheme 1.
  • the erythromycin (II) is treated with sodium borohydride in methanol at provide the ( 9S )-9-dihydroerythromycin, (III).
  • Compound (III) is demethylated, for example using iodine and light in buffered methanol or using N-iodosuccinimide in acetonitrile, to provide compound (IV).
  • Reaction of the erythromycin (II) wherein R 3 and R 4 are both OH with a carbonylating reagent, for example ethylene carbonate or 1,1-carbonyldiimidazole, in the presence of a base, for example potassium carbonate or 4-(dimethylamino)pyridine provides the 11,12-cyclic carbonate.
  • the cyclic carbonates are then converted into the final products according to the method illustrated in Scheme 1.
  • the erythromycins of formula (II) are prepared as illustrated in Scheme 3 and described in U.S. Patents 6,066,721 ; 6,261,816 ; and 6,395,710 .
  • a diketide thioester of formula (V) is supplied to a polyketide synthase to produce a polyketide of structure (VI).
  • the preparation of diketide thioesters is described in WO 00/44717 .
  • the polyketide synthase is a 6-deoxyerythronolide B synthase or an 8,8a-deoxyoleandolide synthase.
  • 6-deoxyerythronolide B synthases are found in, for example, Saccharopolyspora erythraea , as described in U.S. Patent 5,824,513 , and in Micromonospora megalomicea , as described in WO 01/27284 .
  • An example of an 8,8a-deoxyoleandolide synthase is found in Streptomyces antibioticus , as described in U.S. Patent 6,251,636 .
  • These polyketide synthases are modified so as to prevent the incorporation of their native starter units. Methods of mutating polyketide synthases so as to prevent the incorporation of native starter units, for example by inactivation of the module 1 ketosynthase, are described in U.S. Patent 6,066,721 .
  • the diketide thioester (V) may be supplied to a cell-free form of the polyketide synthase, as described in U.S. Patent 6,080,555 , it is more convenient to feed (V) to a culture of an organism expressing the mutated polyketide synthase.
  • the organism can be an actinomycete, such as a Streptomyces or Saccharopolyspora , preferably Streptomyces coelicolor , as described in U.S. Patent 6,066,721 and in PCT publication WO 01/83803 , or a non-actinomycete such as Escherichia coli or Saccharomyces cerevesiae as described in WO 01/31035 .
  • Methods for producing suitable mutated polyketide synthases are described, for example, in U.S. patents 6,391,594 and 6,403,775 .
  • Polyketide (VI) is converted into a erythromycin (II) through a series of tailoring steps that include hydroxylation at C-6, addition of mycarose to the 3-OH, addition of desosamine to the 5-OH, hydroxylation at C-12, and methylation at the mycarose 3"-OH.
  • Other forms of the erythromycin can be prepared using the appropriate subset of tailoring enzymes.
  • This tailoring is most conveniently done by supplying polyketide (VI) to a culture of an organism expressing all the necessary enzymes for the transformations, for example a mutant of Saccharopolyspora erythraea comprising an inactive polyketide synthase as described in U.S. Patent 6,395,710 .
  • a method for this process is detailed in Example 2 below.
  • the compounds of formula (I) are agonists of the motilin receptor.
  • Table 1 shows the EC 50 values for activation of the motilin receptor, as measured by a calcium-influx assay as described in Carreras et al., Anal. Biochem. 300,146-151 (2002 ).
  • Table 1 Motilin Receptor Activation Compound Ref.
  • R 1 R 2 R 3 R 4 EC 50 ( ⁇ M) Erythromycin
  • Antibacterial activity was determined by in vitro susceptibility tests against Streptococcus pneumoniae ATCC 6301, a macrolide-sensitive strain, using methods known in the microbiological art.
  • Table 2 In vitro Minimum Inhibitory Concentrations Against ATCC 6301 Compound I MIC ( ⁇ g/mL) Erythromycin A 0.03 A 0.3 F 1 G >100 J >100
  • Another aspect of the present invention provides the use of compounds having formula (I) for the preparation of a medicament for the treatment of impaired gastric motility.
  • using the compounds of the present invention comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention.
  • disorders include gastroparesis, gastroesophageal reflux disease, anorexia, gall bladder stasis, postoperative paralytic ileus, scleroderma, intestinal pseudo-obstruction, gastritis, emesis, and chronic constipation (colonic inertia).
  • the therapeutically effective amount can be expressed as a total daily dose of the compound or compounds of this invention and may be administered to a subject in a single or in divided doses.
  • the total daily dose can be in amounts, for example, of from about 0.01 to about 10 mg/kg body weight, or more usually, from about 0.1 to about 2 mg/kg body weight.
  • Single dose compositions may contain such amounts or submultiples thereof as to make up the daily dose.
  • treatment regimens according to the present invention comprise administration to a subject in need of such treatment of from about 10 mg to about 1000 mg of the compound(s) of the present invention per day in single or multiple doses.
  • the inventive compound will be part of a pharmaceutical composition or preparation that may be in any suitable form such as solid, semisolid, or liquid form.
  • the pharmaceutical preparation will contain one or more of the compounds of the invention as an active ingredient and a pharmaceutically acceptable carrier.
  • the active ingredient is in admixture with an organic or inorganic carrier or excipient suitable for external, enteral, or parenteral application.
  • the active ingredient may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, pessaries, solutions, emulsions, suspensions, and any other form suitable for use.
  • Oral dosage forms may be prepared essentially as described by Hondo et al., 1987, Transplantation Proceedings XIX, Supp. 6: 17-22 ,.
  • the carriers that can be used include water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, cornstarch, keratin, colloidal silica, potato starch, urea, and other carriers suitable for use in manufacturing preparations, in solid, semi-solid, or liquified form.
  • auxiliary stabilizing, thickening, and coloring agents and perfumes may be used.
  • the compounds of the invention may be utilized with hydroxypropyl methylcellulose essentially as described in U.S. Patent No. 4,916,138 , or with a surfactant essentially as described in EPO patent publication No. 428,169 .
  • the present invention provides motilide compounds and their use, which are further illustrated by the following examples.
  • 15-methyl-6-deoxyerythronolide B also referred to as 13-propyl-6-dEB or 15-methyl-6-dEB
  • 15-fluoro-6-dEB 15-fluoro-6-dEB
  • a 1 mL vial of the CH999/pJRJ2 Streptomyces coelicolor that contains a PKS in which the ketosynthase domain of module 1 has been inactivated by mutation
  • working cell bank is thawed and the contents of the vial are added to 50 mL of Medium 1 in a 250 mL baffled flask.
  • Medium 1 comprises 45 g/L cornstarch; 10 g/L corn steep liquor; 10 g/L dried, inactivated brewers yeast; and 1 g/L CaCO 3 .
  • This solution is sterilized by autoclaving for 90 minutes at 121°C. After sterizilization, 1 mL/L of sterile filtered 50 mg/ml thiostrepton in 100% DMSO and 1 mL/L autoclaved 100% antifoam B silicon emulsion (J.T. Baker) are added prior to use.
  • the flask containing the thawed cells and Medium 1 is placed in an incubator/shaker maintained at 30 ⁇ 1°C and 175 ⁇ 25 RPM for 48 ⁇ 10 hours.
  • the 50 mL culture is then added to a 2.8 L baffled flask containing 500 mL of Medium 1.
  • This flask is incubated in an incubator/ shaker at 30 ⁇ 1°C and 175 ⁇ 25 RPM for 48 ⁇ 10 hours.
  • the 500 mL culture is than used to inoculate a 10 L fermenter containing 5 L of Medium 1.
  • the fermenter is controlled at 30°C, pH 6.5 by addition of 2.5 N H 2 SO 4 and 2.5 N NaOH, agitation rate 600 RPM, and air flow rate 1-2 LPM.
  • Foam is controlled by the addition of a 50% solution of Antifoam B as needed.
  • the fermenter culture is allowed to grow under these conditions for 24 ⁇ 5 hours.
  • a 150 L fermenter is prepared by sterilizing 100 L of Medium 1 at 121°C for 45 minutes. After the growth period, the contents from the 10 L fermenter are aseptically added to a 150 L fermenter.
  • the fermenter is controlled at 30°C, pH 6.5 by addition of 2.5 N H 2 SO 4 and 2.5 N NaOH, dissolved oxygen ⁇ 80% air saturation by agitation rate (500-700 RPM), air flow rate (10-50 LPM), and/ or back pressure control (0.1-0.4 bar).
  • Foam is controlled by the addition of a 50% solution of Antifoam B as needed.
  • HP20 resin Mitsubishi resin (Mitsubishi). Column size is selected based on supernatant volume and titer, so that the loading capacity of 15 g 15-methyl-6-dEB per liter HP20 resin is not exceeded.
  • the centrifuged broth is passed through the resin bed at a linear flow rate of 300 ⁇ 20 cm/h. The pressure on the column should not exceed 15 psi.
  • the resin is then washed with 2 column volumes (CV) of water and then 2 CV of 30 % methanol, each at a rate of 300 ⁇ 20 cm/ h. 13-propyl-6-dEB is eluted using 7-10 CV 100% methanol at a rate of 300 ⁇ 20 cm/h.
  • fractions of 1 CV are collected.
  • the fractions are then analyzed, and those containing product are combined to yield a product pool containing >95% of the original 15-methyl-6-dEB in the centrifuged broth.
  • the product pool is reduced to solids using rotary evaporation.
  • Product purity at this stage is 5-35%.
  • Methanol-insoluble material is removed from the product pool by suspending the solids in 3 L 100% methanol per 100 L original broth volume, mixing for 20 minutes, and filtering.
  • the final purification step is chromatography using HP20SS resin (Mitsubishi). Column size is selected based on amount of product, so that the loading capacity of 15 g 15-methyl-6-dEB per liter HP20SS resin is not exceeded.
  • the filtered methanol solution is diluted by adding an equal volume of water.
  • the 50% methanol solution is passed through the resin bed at a linear flow rate of 300 ⁇ 20 cm/h.
  • the column is then washed with 2 CV of 50% methanol at a rate of 300 ⁇ 20 cm/h.
  • Product is eluted using 12 CV 70% methanol at a rate of 300 ⁇ 20 cm/h. During elution, fractions of 1 CV are collected.
  • fractions are then analyzed, and those containing >50 mg/L 15-methyl-6-dEB and having >20% chromatographic purity are combined.
  • the product pool is reduced to solids using rotary evaporation. Product purity at this stage is >65% and is suitable for bioconversion to the appropriate erythromycin.
  • a 1 mL vial from working cell bank K39-14V (an eryA mutant of S. erythraea that is incapable of producing 6-dEB) is thawed and the contents of the vial are added to 50 mL of Medium 2 in a 250 mL baffled flask.
  • Medium 2 comprises 16 g/L cornstarch; 10 g/L corn dextrin; 15 g/L soy meal flour; 4 g/L CaCO 3 ; 5 g/L corn steep liquor; 6 g/L soy bean oil; 2.5 g/L NaCl; and 1 g/L (NH 4 ) 2 SO 4 .
  • This solution is sterilized by autoclaving for 60 minutes at 121 °C and 1 mL/L autoclaved 100% antifoam B silicon emulsion (J.T. Baker) is added prior to use.
  • the flask containing the thawed cells and Medium 2 is placed in an incubator/shaker maintained at 34 ⁇ 1°C and 175 ⁇ 25 RPM for 48 ⁇ 10 hours.
  • the 50 mL culture is then added to a 2.8 L baffled flask containing 500 mL of Medium 2.
  • the flask is incubated in an incubator/shaker at 34 ⁇ 1°C and 175 ⁇ 25 RPM for 48 ⁇ 10 hours.
  • the 500 mL culture is than used to inoculate a 10 L fermenter containing 5 L of Medium 2.
  • the fermenter is controlled at 34°C, pH 7.0 by addition of 2.5 N H 2 SO 4 and 2.5 N NaOH, agitation rate 600 RPM, and air flow rate 1-2 LPM.
  • Foam is controlled by the addition of a 50% solution of Antifoam B as needed.
  • the fermenter culture is allowed to grow under these conditions for 24 ⁇ 5 hours.
  • a 150 L fermenter is prepared by sterilizing 100 L of Medium 3 at 121°C for 45 minutes.
  • Medium 3 comprises 17.5 g/L cornstarch; 16 g/L corn dextrin; 16.5 g/L soy meal flour; 4 g/L CaCO 3 ; 6 g/L corn steep liquor; 3 g/L soy bean oil; 3.5 g/L NaCl; and 1 g/L (NH 4 ) 2 SO 4 .
  • the contents from the 10 L fermenter are aseptically transferred to the 150 L fermenter.
  • the fermenter is controlled at 34°C, pH 7.0 by addition of 2.5 N H 2 SO 4 and 2.5 N NaOH, dissolved oxygen ⁇ 80% air saturation by agitation rate (500-700 RPM), air flow rate (15-50 LPM), and/or back pressure control (0.1-0.4 bar).
  • Foam is controlled by the addition of a 50 % solution of Antifoam B.
  • a 58-60 mL/hour 15% dextrin (w/v) feed is initiated.
  • the dextrin solution is continuously mixed during the feed period.
  • 25 grams of 13-propyl-6dEB are added to the fermenter.
  • the 13-propyl-6dEB is prepared by solubolizing 25 grams of 13-propyl-6dEB in 400-600 mL of 100% ethanol and filtering (0.2 ⁇ m, nylon filter). Conversion of 13-propyl-6dEB to 13-propyl-erythromycin A ceases after 60 ⁇ 10 hours and the fermenter is harvested.
  • the fermentation broth is centrifuged at 20,500 g in an Alpha Laval AS-26 centrifuge. The product is predominantly in the supernatant; the centrifuged cell mass is discarded.
  • HP20 resin Mitsubishi resin (Mitsubishi). Column size is selected based on supernatant volume and titer, so that the loading capacity of 15 g 15-methylerythromycin A per liter HP20 resin is not exceeded.
  • the centrifuged broth is adjusted to pH 9, then passed through the resin bed at a linear flow rate of 275 ⁇ 25 cm/h. The pressure on the column should not exceed 15 psi.
  • the resin is then washed with 1 column volume (CV) of water at a rate of 275 ⁇ 25 cm/h.
  • the 15-methylerythromycin is eluted using 5 CV 100% methanol at a rate of 275 ⁇ 25 cm/h.
  • fractions of 1 CV are collected.
  • the fractions are then analyzed, and those containing product are combined to yield a product pool.
  • the product pool is reduced to solids using rotary evaporation.
  • Methanol-insoluble material is removed from the product pool by suspending the solids in 1L 100% methanol per 100 L original broth volume, adjusting to pH 9, and filtering.
  • the product pool (filtrate) is reduced to solids using rotary evaporation.
  • the 15-methylerythromycin A is extracted from the product pool (solids) by adding 2 L 4:1 hexane:acetone per 100 L original broth volume, mixing for 20 minutes, and filtering. The remaining solids are extracted the same way two more times and filtrates are combined.
  • the product pool is reduced to solids using rotary evaporation.
  • the final purification step is chromatography using HP20SS resin (Mitsubishi). Column size is selected based on amount of product, so that the loading capacity of 15 g 15-methylerythromycin A per liter HP20SS resin is not exceeded.
  • the solids from the previous steps are dissolved in 1 L methanol per 100 L original broth volume, and an equal volume of water is added.
  • the 50% methanol solution is passed through the resin bed at a linear flow rate of 275 ⁇ 25 cm/h.
  • the column is then washed with 1 CV of 50% methanol, then 3 CV 60% methanol, each at a rate of 275 ⁇ 25 cm/h.
  • Product is eluted using 3 CV 70% methanol, then 10 CV 75% methanol, each at a rate of 275 ⁇ 25 cm/h.
  • fractions of 1 CV are collected.
  • the fractions are then analyzed, and those containing 15-methylerythromycin A are combined.
  • the product pool is reduced to solids using rotary evaporation.
  • 15-fluoroerythromycin A is prepared using 15-fluoro-6-dEB.
  • the crude product was purified via silica gel column chromatography (3:1 hexane-acetone, 1% triethylamine) to give pure N-desmethyl-N-isopropyl-15-methylerythromycin A (1.80 g, 75% yield for 2 steps). ).
  • N-desmethyl-N-isopropyl-15-methylerythromycin A (1.74 g, 2.24 mmol) was dissolved in methanol-ether (1:3 V/V, 50 mL), then cooled to -20 °C.
  • Sodium borohydride (189 mg, 5.0 mmol) was added.
  • the mixture was then warmed slowly to room temperature over a period of 3 h.
  • the excess sodium borohydride was destroyed by addition of pH 6.0 phosphate buffer, followed by triethanolamine (10 mL). After 30 min the mixture was extracted with ethyl acetate and dried over magnesium sulfate.
  • the crude product was purified by silica gel column chromatography (3:1 hexane-acetone with 1% triethylamine).
  • This example describes the construction of a strain of Saccharopolyspora erythraea (K24-1/159-44) capable of the biosynthesis of 11-deoxyerythromycins, with particular reference to 11-deoxyerythromycin B, which are useful as intermediates for the synthesis of certain compounds of this invention.
  • 11-Deoxyerythromycin B can be prepared in a single fermentation in a genetically engineered host cell expressing a modified version of the DEBS suite of genes ( eryAI, eryAII , and enyAIII ).
  • the enyAI gene is engineered by replacement of the ketoreductase domain in module 2 with a cassette containing a dehydratase domain, an enoylreductase domain, and a ketoreductase domain, for example taken from module 1 of the rapamycin PKS.
  • Methods for domain replacement are provided in, for example, McDaniel, US 6,403,775 (2002 ), which is incorporated herein by reference.
  • the engineered eryAI gene is incorporated along with the eryAII and eryAIII genes into a host cell competent in the production of erythromycins once the engineered PKS genes have been added.
  • these host cells are "clean hosts," wherein their native PKS genes have been removed.
  • suitable hosts include but are not limited to the clean host Saccharopolyspora erythraea K24-1 and strains of Saccharopolyspora erythraea having mutated PKS genes such as those described in Santi et al., US 2002/ 0004229 A1 ( 2002 ).
  • Strain K24-1 has had the native eryAI, eryAII, and eryAIII genes replaced with the attB phage attachment site of the actinophage ⁇ C31, described in U.S. Patent 5,190,871 , incorporated herein by reference, and followed by the ermE * promoter.
  • This allows plasmid vectors comprising the complementary attP phage attachment site along with the genes to be delivered to integrate into the chromosome at the attB site in the presence of a phage integrase.
  • suitable integrating phage vectors include but are not limited to pSET152 and its derivatives.
  • pKOS159-8 and pKOS159-10 are derivatives of pSET152 containing the eryA genes under the control of the ermE p* promoter and the actI p/ actII -ORF4 promoter-activator pair, respectively.
  • a 35 kb Nsi I fragment from pKAO127 carrying the eryA genes and the actI p/ actII -ORF4 region was cloned into pKOS97-64c (a pSET152 derivative containing the ermE p* promoter and a ⁇ cos site) to make pKOS159-10.
  • the fd transcriptional terminator from the pKAO127 fragment prevents expression of any genes from the ermE p* promoter in this plasmid.
  • the fragment containing the fd terminator and actI p/ actII -ORF4 segment in pKOS159-10 was removed by digestion with Pac I and self-ligation to generate pKOS159-8.
  • pKOS159-31 For expression of eryA genes under their natural promoter, pKOS159-31 was constructed by cloning the Nde I- Xba I fragment carrying the eryA genes (and ⁇ cos site) from pKOS159-10 and the Xba I- Nde I digested PCR amplified eryAI left flank fragment from above into pSET152 digested with Xba I. pKOS159-33, which contains the eryA genes from S. erythraea K41-135 was constructed in an analogous way using the eryA fragment from pKOS108-04. Likewise, all engineered DEBS expression plasmids were made using pKOS159-31 as a scaffold and appropriate restriction enzymes to move the genetically modified eryA fragment from existing plasmids.
  • pKOS159-44 is a pSET152 ( Bierman et al., Gene 116, 43-49 (1992 ), "Plasmid cloning vectors for the conjugal transfer of DNA from Escherichia coli to Streptomyces spp.") derivative plasmid that has genetically modified eryA genes (KR2 ⁇ rapDH/ER/KR1) under the control of eryAI promoter ( Rodriguez et al., J. Ind. Microbio. Biotechnol., "Rapid Engineering of Polyketide Overproduction by Gene Transfer to Industrially Optimized Strains," web-published as document no. 10.1007/s10295-003-0045-1 (http://link.springer-ny.com) (16 Apr.
  • a 30 kb Nde I- Nsi I fragment (carrying genetically modified eryA genes) from pKOS11-66 ( Xue et al., Proc. Natl. Acad. Sci. U.S.A., 96,11740-11745 (1999 ), "A multiplasmid approach to preparing large libraries of polyketides" was isolated and ligated to a 8 kb Nde I- Nsi I fragment from pKOS159-33 (Rodriguez et al., cited supra ), containing the vector pSET152, eryAp promoter and cos ⁇ site).
  • the ligation mixture was packaged using Gigapack III Gold packaging extract (Stratagene), and used to infect E . coli XL-1 Blue. Recombinats were selected on LB agar plates containing 60 ⁇ g/ml apramycin. pKOS159-44 plasmid DNA was isolated and checked by restriction digestions.
  • S . erythraea strain K24-1 which contains a chromosomal deletion of the three eryA genes and insertion of the attB loci for the Streptomyces phage ⁇ C31 from Streptomyces lividans, followed by the ermE * promoter in their place, was prepared by harvesting spores from strains grown on 1-2 M1 plates (per liter, 5 g glucose, 5 g tryptone, 0.5g betaine hydrochoride, 5g corn starch, 1g corn steep liquor (50%), 200 mg MgSO 4 •7H 2 O, 2 mg ZnSO 4 •7H 2 O, 0.8 mg CuSO 4 •5H 2 O, 0.2 mg CoCl 2 •6H 2 O, 4 mg FeSO 4 •7H 2 O, 80 mg CaCl 2 •6H 2 O, 150 mg KH 2 PO 4 , 10 g NaCl, 20 g agar) filtering the spores through sterile cotton, and resuspending
  • the cells were grown at 37°C for 3-4 h (OD 600 of 0.4-0.6), collected by centrifugation, washed in 5 mL LB, centrifuged, and resuspended in 100 ⁇ L of LB. Conjugal transfer between the donor and recipient cells was performed by resuspending the recipient cells in the 100 ⁇ l donor suspension and the cells were spread on R5 plates ( Hopwood et al., Genetic Manipulation of Streptomyces: A Laboratory Manual (The John Innes Foundation, Norwich, UK, 1985 ) containing 50 ⁇ g/mL nalidixic acid and incubated at 34°C for 16 h. The plates were then overlayed with 3 mL of soft nutrient agar containing 1 mg nalidixic acid and 2 mg apramycin. Exconjugants K24-1/159-44 were observed after 48 h of further incubation.
  • This example describes the biosynthesis of 11-deoxyerythromycin B, an intermediate for the synthesis of certain compounds of this invention, using the strain described in the preceding example.
  • Seed medium V1 contained 16 g/L corn starch, 10 g/L dextrin (D-2256, Sigma-Aldrich), 15 g/L soybean flour (S-9633, Sigma-Aldrich), 2.5 g/L sodium chloride, 5 g/L corn steep liquor, 1 g/L ammonium sulfate (A-2939, Sigma-Aldrich), 6 g/L soybean oil (S-7381, Sigma-Aldrich), and 4 g/L calcium carbonate (C-4830, Sigma Aldrich).
  • Fermentation medium F2 contained 28 g/L corn starch, 24 g/L soybean meal, 5.5 g/L sodium chloride, 8 g/L corn steep liquor, and 1.5 g/L ammonium sulfate, 4.5 g/L soybean oil, and 6 g/L calcium carbonate. All media were sterilized by autoclaving at 121°C for 90 min.
  • Two seed flasks were started by taking a 1 mL vial of Saccharopolyspora erythraea K24-1/pKOS159-44 from a frozen cell bank, thawing, and adding the vial contents into 50 mL of medium V1 and incubating at 34 °C for 40-48 h.
  • Two secondary seeds were then created by transferring 50 mL aliquots from the seed flask to 500 mL of medium V1 and incubating at 34 °C for 40-48 h.
  • Both 500 mL secondary seed cultures were transferred to a B. Braun B10 fermenter containing 9 L of medium V1.
  • the fermenter was operated at 34°C and maintained at pH 7.0 by addition of 2.5 N sulfuric acid and 2.5 N sodium hydroxide. Aeration at 3 LPM and agitation at 600 to 800 rpm were provided, maintaining the dissolved oxygen tension at greater than 40%. Harvesting took place after about 24 h.
  • Foaming was controlled by the addition of a 50% solution of antifoam B (JT Baker) as needed.
  • the fermentation broth was clarified by centrifugation and was subjected to solid phase extraction using HP20 resin (Mitsubishi). Adsorbed product was eluted with methanol and dried. The crude product was then subjected to ethyl acetate:water liquid:liquid extraction. The combined ethyl acetate extracts were dried. The product was purified by chromatography using HP20SS resin, eluting with a step-gradient from 50% to 80% methanol. The product containing fractions were pooled and dried, to provide 11-deoxyerythromycin B.
  • 11-Deoxyerythromycin B (200 mg, 0.285 mmol) was reduced generally following the procedure of Example 8 to give (9S)-9-dihydroerythromycin B (94 mg, 47% yield).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Claims (15)

  1. Composé ayant la formule (I)
    Figure imgb0027
     ou sel pharmaceutiquement acceptable correspondant,
    dans lequel
    R1 représente alkyle en C1-C1 substitué, alkényle en C1-C10 substitué ou non substitué, alkynyle en C2-C10 substitué ou non substitué, aryle substitué ou non substitué, ou hétérocyclo substitué ou non substitué;
    R2 représente H, alkyle en C1-C5 substitué ou non substitué, alkényle en C2-C5substitué ou non substitué, alkynyle en C2-C5 substitué ou non substitué, aryle substitué ou non substitué, ou hétérocyclo substitué ou non substitué;
    R3 représente H ou OH;
    R4 représente H ou OH, ou R3 et R4, pris ensemble, représentent O-(C=O)-O,
    étant entendu que, lorsque (a) R1 représente éthyle et (b) R3 représente OH, ou R34 et R4, pris ensemble, représentent O-(C=O)-O, dans ce cas, R2 ne représente pas H ou méthyle.
  2. Composé selon la revendication 1, dans lequel ou sel pharmaceutiquement acceptable correspondant dans lequel
    R1 représente alkyle en C1-C1 substitué, alkényle en C1-C10 substitué ou non substitué, alkynyle en C2-C10 substitué ou non substitué, aryle substitué ou non substitué, ou hétérocyclo substitué ou non substitué;
    R2 représente H, éthyle, propyle, isopropyle ou 2-butyle; et
    R3 et R4 représente OH;
    étant entendu que, lorsque R1 représente éthyle, R2 ne représente pas H ou méthyle.
  3. Composé selon la revendication 1, dans lequel
    R1 représente alkyle en C1-C5 substitué ou non substitué,
    R2 représente H, alkyle en C1-C5 substitué ou non substitué, alkényle en C2-C5 substitué ou non substitué, alkynyle en C2-C5 substitué ou non substitué, et
    R3 et R4 représentent OH,
    étant entendu que, lorsque R1 représente éthyle, R2 ne représente pas H ou méthyle.
  4. Composé selon la revendication 1, dans lequel
    R1 représente éthyle,
    R2 représente éthyle, propyle, isopropyle ou 2-butyle ; et
    R3 et R4 représentent OH.
  5. Composé selon la revendication 1, dans lequel
    R1 représente éthyle substitué,
    R2 représente H, alkyle en C1-C5 substitué ou non substitué, alkényle en C2-C5 substitué ou non substitué, alkynyle en C2-C5 substitué ou non substitué, et
    R3 et R4 représentent OH.
  6. Composé selon la revendication 1, dans lequel
    R1 représente éthyle substitué,
    R2 représente H, éthyle, propyle, isopropyle ou 2-butyle ;et
    R3 et R4 représentent OH.
  7. Composé selon la revendication 1, dans lequel
    R1 représente propyle,
    R2 représente H, alkyle en C1-C5 substitué ou non substitué, alkényle en C2-C5 substitué ou non substitué, ou alkynyle en C2-C5 substitué ou non substitué, et
    R3 et R4 représentent OH.
  8. Composé selon la revendication 1, dans lequel
    R3 et R4 représentent indépendamment H ou OH ;
    R1 est sélectionné dans le groupe consistant en éthyle, 2-fluoroéthyle et 1-propyle ; et
    R2 est sélectionné dans le groupe consistant en méthyle, éthyle, isopropyle et 2-butyle ;
    étant entendu que, lorsque R1 représente éthyle et que R3 représente OH, R2 ne représente pas méthyle.
  9. Composé selon la revendication 1, dans dans lequel R1 R2, R3 et R4 sont selon les combinaisons indiquées dans le tableau ci-dessous : R1 R2 R3 R4 CH3CH2 CH(CH3)2 OH OH FCH2CH3 CH, OH OH FCH2CH3 CH2CH3 OH OH FCH2CH3 CH(CH3)2 OH OH CH3CH2CH2 CH3 OH OH CH3CH2CH2 CH(CH3)2 OH OH CH3CH2CH2 C(CH3)CH2CH3 OH OH CH3CH2 CH(CH3)2 H H
  10. Composé selon la revendication 1, sélectionné dans le groupe consistant en :
    Figure imgb0028
    Figure imgb0029
    Figure imgb0030
     et
    Figure imgb0031
  11. Composé selon la revendication 1, ayant une structure de formule :
    Figure imgb0032
  12. Composé selon la revendication 1, ayant une structure de formule :
    Figure imgb0033
  13. Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1 à 12, avec un support pharmaceutiquement acceptable.
  14. Composé selon l'une quelconque des revendications 1 à 12, pour une utilisation dans le traitement d'un trouble de la mobilité gastrique.
  15. Utilisation d'un composé selon l'une quelconque des revendications 1 à 12, pour la préparation d'un médicament pour le traitement d'un trouble gastrique chez un patient.
EP03755757A 2002-08-29 2003-08-26 Composes du type motilide Expired - Lifetime EP1532131B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI200331492T SI1532131T1 (sl) 2002-08-29 2003-08-26 Motilidne spojine
CY20091100165T CY1108808T1 (el) 2002-08-29 2009-02-13 Ενωσεις μοτιλιδης

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40734502P 2002-08-29 2002-08-29
US407345P 2002-08-29
PCT/US2003/026991 WO2004019879A2 (fr) 2002-08-29 2003-08-26 Composes du type motilide

Publications (3)

Publication Number Publication Date
EP1532131A2 EP1532131A2 (fr) 2005-05-25
EP1532131A4 EP1532131A4 (fr) 2007-05-30
EP1532131B1 true EP1532131B1 (fr) 2008-12-17

Family

ID=31978464

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03755757A Expired - Lifetime EP1532131B1 (fr) 2002-08-29 2003-08-26 Composes du type motilide

Country Status (15)

Country Link
US (1) US6946482B2 (fr)
EP (1) EP1532131B1 (fr)
JP (1) JP4796300B2 (fr)
KR (1) KR101051613B1 (fr)
CN (1) CN100363359C (fr)
AT (1) ATE417856T1 (fr)
AU (1) AU2003273254B2 (fr)
CA (1) CA2492846C (fr)
CY (1) CY1108808T1 (fr)
DE (1) DE60325377D1 (fr)
DK (1) DK1532131T3 (fr)
ES (1) ES2316805T3 (fr)
PT (1) PT1532131E (fr)
SI (1) SI1532131T1 (fr)
WO (1) WO2004019879A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063021B2 (en) 2002-01-17 2011-11-22 Kosan Biosciences Incorporated Ketolide anti-infective compounds
US7407941B2 (en) * 2003-08-26 2008-08-05 Pfizer, Inc. N-desmethyl-N-substituted-11-deoxyerythromycin compounds
GB0327720D0 (en) * 2003-11-28 2003-12-31 Biotica Tech Ltd Erythromycins and process for their preparation
US7211568B2 (en) * 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
CN101203227B (zh) * 2005-05-24 2011-01-12 辉瑞大药厂 促动内酯类化合物
US7582611B2 (en) * 2005-05-24 2009-09-01 Pfizer Inc. Motilide compounds
US20070135362A1 (en) * 2005-12-08 2007-06-14 Yaoquan Liu Method for demethylating the 3'-dimethylamino group of erythromycin compounds
US9133235B2 (en) 2006-09-11 2015-09-15 Ocera Therapeutics, Inc. Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders
NZ576719A (en) * 2006-12-05 2012-01-12 Pfizer Motilide polymorphs
US20080287371A1 (en) * 2007-05-17 2008-11-20 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
CN106138038B (zh) * 2015-04-28 2021-04-20 天津国际生物医药联合研究院 大环内酯类衍生物及其用途
CN106478541A (zh) * 2016-10-17 2017-03-08 南开大学 大环内酯类衍生物及其用途
CN106478542A (zh) * 2016-10-17 2017-03-08 南开大学 一种大环内脂类衍生物盐、其制备方法及用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US391594A (en) * 1888-10-23 Arc-extinguisher for electric switches or cut-outs
US4382086A (en) 1982-03-01 1983-05-03 Pfizer Inc. 9-Dihydro-11,12-ketal derivatives of erythromycin A and epi-erythromycin A
US4382085A (en) 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
PL136968B1 (en) 1983-02-10 1986-04-30 Tarchominskie Zaklad Farma Process for preparing cyclic 11,12-carbonate of erythromycin a
JPS60218321A (ja) 1984-04-13 1985-11-01 Satoshi Omura 消化管収縮運動促進剤
EP0184921A3 (fr) * 1984-12-08 1986-10-29 Beecham Group Plc Dérivés d'érythromycine
GB8608080D0 (en) 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
US4742049A (en) * 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
US4857641A (en) 1987-08-14 1989-08-15 Pfizer Inc. C.12 modified erythromycin A derivatives
GR1000519B (el) 1989-03-28 1992-08-25 Abbott Lab Παραγωγα ερυθρομυκινης.
US5190871A (en) 1989-06-12 1993-03-02 Eli Lilly And Company Use of the site-specific integrating function of phage φC31
US5824513A (en) 1991-01-17 1998-10-20 Abbott Laboratories Recombinant DNA method for producing erythromycin analogs
US5554605A (en) 1991-04-09 1996-09-10 Abbott Laboratories Macrocyclic lactam prokinetic agents
ATE139697T1 (de) 1991-04-09 1996-07-15 Abbott Lab Macrozyklische laktam-prokinetika
IL104437A (en) 1992-01-21 1997-03-18 Abbott Lab 4)-deoxyerythromycin derivatives
MY113693A (en) 1992-05-26 2002-05-31 Chugai Pharmaceutical Co Ltd Erythromycin derivatives having an enterokinesis stimulating action
US6066721A (en) 1995-07-06 2000-05-23 Stanford University Method to produce novel polyketides
US5712146A (en) 1993-09-20 1998-01-27 The Leland Stanford Junior University Recombinant combinatorial genetic library for the production of novel polyketides
EP0836649B1 (fr) 1995-07-06 2004-12-29 The Leland Stanford Junior University Synthese de polycetides, exempte de cellule
US6077943A (en) 1996-03-01 2000-06-20 Takeda Chemical Industries, Ltd. Method of producing erythromycin derivative
WO1997035590A1 (fr) * 1996-03-25 1997-10-02 Platt Chris E 10-aza-9-deoxo-11-deoxy-erythromycine a et derives combines a du sulfisoxazole
US5712253A (en) 1996-06-18 1998-01-27 Abbott Laboratories Macrocyclic 13-membered ring derivatives of erythromycins A and B
US6271255B1 (en) * 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
US5922849A (en) 1996-11-22 1999-07-13 Abbott Laboratories Process for preparation of N-demethyl-4"-deoxy-erthromycins A and B
WO1998040392A1 (fr) * 1997-03-10 1998-09-17 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
US6169168B1 (en) 1997-10-29 2001-01-02 Taisho Pharmaceuticals Co., Ltd. Erythromycin A derivatives
WO1999021867A1 (fr) 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
US6084079A (en) 1998-05-15 2000-07-04 Keyes; Robert F. Process for preparing N-demethyl-N-alkyl erythromycin derivatives
EP1124968A2 (fr) * 1998-10-28 2001-08-22 Kosan Biosciences, Inc. Banque de nouveaux produits naturels non naturels
CA2347412A1 (fr) 1998-10-29 2000-05-11 Kosan Biosciences, Inc. Oleandolide-polyketide-synthase de recombinaison
AU3353500A (en) 1999-01-27 2000-08-18 Kosan Biosciences, Inc. Synthesis of oligoketides
ATE340183T1 (de) * 1999-04-16 2006-10-15 Kosan Biosciences Inc Antiinfektiöse makrolidderivate
US6524841B1 (en) 1999-10-08 2003-02-25 Kosan Biosciences, Inc. Recombinant megalomicin biosynthetic genes and uses thereof
DE60033835T2 (de) 1999-10-27 2007-11-15 Kosan Biosciences, Inc., Hayward Heterologe herstellung von polyketiden
AU2001238476A1 (en) * 2000-02-18 2001-08-27 Kosan Biosciences, Inc. Motocide compounds
WO2001083803A1 (fr) 2000-05-02 2001-11-08 Kosan Biosciences, Inc. Surproduction d'hotes utilisee dans la biosynthese de polyketides
US20020094962A1 (en) 2000-12-01 2002-07-18 Gary Ashley Motilide compounds
EP1337540A2 (fr) * 2000-12-01 2003-08-27 Kosan Biosciences, Inc. Composes de motilide
JP2004530108A (ja) 2001-02-15 2004-09-30 コーサン バイオサイエンシーズ， インコーポレイテッド 治療効力を評価するための方法
EP1404693A2 (fr) * 2001-07-03 2004-04-07 Chiron Corporation Macrolides et cetolides d'erythromycine modifiee c12 a activite antibacterienne
ITMI20021726A1 (it) * 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.

Also Published As

Publication number Publication date
ES2316805T3 (es) 2009-04-16
AU2003273254A1 (en) 2004-03-19
EP1532131A2 (fr) 2005-05-25
DE60325377D1 (de) 2009-01-29
US6946482B2 (en) 2005-09-20
EP1532131A4 (fr) 2007-05-30
WO2004019879A2 (fr) 2004-03-11
JP4796300B2 (ja) 2011-10-19
WO2004019879A3 (fr) 2004-06-03
US20040138150A1 (en) 2004-07-15
ATE417856T1 (de) 2009-01-15
CA2492846C (fr) 2012-09-25
KR101051613B1 (ko) 2011-07-25
WO2004019879A8 (fr) 2004-07-29
SI1532131T1 (sl) 2009-04-30
CY1108808T1 (el) 2014-04-09
DK1532131T3 (da) 2009-02-09
CN100363359C (zh) 2008-01-23
JP2005537317A (ja) 2005-12-08
CN1665799A (zh) 2005-09-07
PT1532131E (pt) 2009-02-18
KR20050038594A (ko) 2005-04-27
CA2492846A1 (fr) 2004-03-11
AU2003273254B2 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
US6458771B1 (en) Ketolide antibacterials
EP1532131B1 (fr) Composes du type motilide
ES2337424T3 (es) Gen poliquetido sintasa i hibrido.
US6750205B2 (en) Motilide compounds
AU4457800A (en) Macrolide antiinfective agents
US20040147461A1 (en) Motilide compounds
JP2004517819A (ja) ケトライド抗菌剤
EP1337540A2 (fr) Composes de motilide
CA2533583C (fr) Composes n-desmethyl-11-desoxyerythromycine n-substitues
US20030199458A1 (en) Amido macrolides
US20050113319A1 (en) 11-Deoxy-6,9-ether erythromycin compounds
WO2003061671A1 (fr) Amido-macrolides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041209

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PFIZER INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20070504

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 17/08 20060101AFI20070426BHEP

Ipc: C07D 313/00 20060101ALI20070426BHEP

Ipc: A61K 31/335 20060101ALI20070426BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SANTI, DANIEL

Inventor name: MCDANIEL, ROBERT

Inventor name: METCALF, BRIAN

Inventor name: RODRIGUEZ, EDUARDO, J.

Inventor name: LIU, YAOQUAN

Inventor name: CARRERAS, CHRISTOPHER

17Q First examination report despatched

Effective date: 20071009

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/04 20060101ALI20080325BHEP

Ipc: A61K 31/7048 20060101ALI20080325BHEP

Ipc: A61P 1/16 20060101ALI20080325BHEP

Ipc: A61P 1/14 20060101ALI20080325BHEP

Ipc: A61P 1/08 20060101ALI20080325BHEP

Ipc: A61P 1/06 20060101ALI20080325BHEP

Ipc: C07D 313/00 20060101ALI20080325BHEP

Ipc: C07H 17/08 20060101AFI20080325BHEP

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. AG PATENT- UND MARKENANWAELTE VSP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60325377

Country of ref document: DE

Date of ref document: 20090129

Kind code of ref document: P

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20090210

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20090400433

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2316805

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E005089

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20090918

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: BRISTOL-MYERS SQUIBB COMPANY

Free format text: PFIZER INC.#235 EAST 42ND STREET#NEW YORK, N.Y. 10017 (US) -TRANSFER TO- BRISTOL-MYERS SQUIBB COMPANY#ROUTE 206 AND PROVINCE LINE ROAD#PRINCETON, NJ 08543-4000 (US)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20120813

Year of fee payment: 10

Ref country code: IE

Payment date: 20120810

Year of fee payment: 10

Ref country code: FI

Payment date: 20120810

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60325377

Country of ref document: DE

Representative=s name: PATENT- UND RECHTSANWAELTE KRAUS & WEISERT, DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 60325377

Country of ref document: DE

Owner name: BRISTOL-MYERS SQUIBB COMPANY, PRINCETON, US

Free format text: FORMER OWNER: PFIZER INC., 10017 NEW YORK, N.Y., US

Effective date: 20130528

Ref country code: DE

Ref legal event code: R082

Ref document number: 60325377

Country of ref document: DE

Representative=s name: KRAUS & WEISERT PATENTANWAELTE PARTGMBB, DE

Effective date: 20130528

Ref country code: DE

Ref legal event code: R081

Ref document number: 60325377

Country of ref document: DE

Owner name: BRISTOL-MYERS SQUIBB COMPANY, US

Free format text: FORMER OWNER: PFIZER INC., NEW YORK, US

Effective date: 20130528

Ref country code: DE

Ref legal event code: R082

Ref document number: 60325377

Country of ref document: DE

Representative=s name: PATENT- UND RECHTSANWAELTE KRAUS & WEISERT, DE

Effective date: 20130528

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20130711

Year of fee payment: 11

Ref country code: LU

Payment date: 20130902

Year of fee payment: 11

Ref country code: HU

Payment date: 20130813

Year of fee payment: 11

Ref country code: DK

Payment date: 20130812

Year of fee payment: 11

Ref country code: EE

Payment date: 20130716

Year of fee payment: 11

Ref country code: BG

Payment date: 20130718

Year of fee payment: 11

Ref country code: PT

Payment date: 20130227

Year of fee payment: 11

Ref country code: AT

Payment date: 20130726

Year of fee payment: 11

Ref country code: CZ

Payment date: 20130808

Year of fee payment: 11

Ref country code: NL

Payment date: 20130810

Year of fee payment: 11

Ref country code: SI

Payment date: 20130717

Year of fee payment: 11

Ref country code: RO

Payment date: 20130711

Year of fee payment: 11

Ref country code: CH

Payment date: 20130813

Year of fee payment: 11

Ref country code: SK

Payment date: 20130812

Year of fee payment: 11

Ref country code: GR

Payment date: 20130723

Year of fee payment: 11

Ref country code: CY

Payment date: 20130718

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20130719

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20130819

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20130819

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: BRISTOL-MYERS SQUIBB COMPANY, US

Effective date: 20131230

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20140306 AND 20140312

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130827

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130826

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130826

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20150226

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20150301

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20140831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140826

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 417856

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140826

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E002952

Country of ref document: EE

Effective date: 20140831

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20090400433

Country of ref document: GR

Effective date: 20150304

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140827

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150301

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140826

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140826

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140826

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150226

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140826

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 5006

Country of ref document: SK

Effective date: 20140826

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140826

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140827

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150304

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140826

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20150409

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140831

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20150925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140827

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140826

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220707

Year of fee payment: 20

Ref country code: DE

Payment date: 20220705

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220709

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60325377

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20230825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230825